View Document Preview and Link Document Date: 2010-08-06 15:45:06 Open Document File Size: 784,70 KB Share Result on Facebook
City Boston / Philadelphia / Memphis / / Company Sanofi Aventis / Ligand / Dana / Merck / Enzon / Medline / HP / / Country United States / / Currency pence / / / Event Product Issues / / Facility Dana-Farber Cancer Institute / St Jude Children’s Research Hospital / University of Tennessee Health Science Center / / IndustryTerm adult protocols / native product / cancer treatment / contemporary protocols / molecular technologies / gene product / altered gene products / model systems / Treatment of acute lymphoblastic leukemia / consecutive treatment protocols / / MedicalCondition adult acute lymphoblastic leukaemia / certain human cancers / T-cell disease / leukaemia research / high-risk acute lymphoblastic leukaemia / malignant disorder / leukaemia control / high-risk leukaemia / acute leukaemia / acute lymphoid leukemia / radiation-induced brain tumours / secondary leukaemia / leukaemia / acute lymphoblastic leukaemia black children / obesity / B-lineage disease / CNS leukaemia / childhood leukaemia cases / common infections / acute lymphoblastic leukaemia need continuation treatment / TEL-AML1-positive leukaemia / Nijmegen breakage syndrome / enzyme deficiency / cancers / profound thrombocytopenia / T-cell acute lymphoblastic leukaemia show / ataxia-telangiectasia / cancer / disease / leukaemia development / T-cell acute lymphoblastic leukaemia / acute lymphocytic leukemia / chromosome-positive disease / pulmonary and neurological events / heterozygous deficiency / Such infectious insulation / adult disease / leukaemia subtypes / tumour / relapsed acute lymphoblastic leukaemia remains / lymphoblastic leukaemia / acute lymphoblastic leukemia / adult acute lymphoblastic leukemia / retinoblastoma pathways / standard-risk acute lymphoblastic leukaemia / very high-risk acute lymphoblastic leukaemia / acute lymphoblastic leukaemia / infant acute lymphoblastic leukaemia / intermediate-risk acute lymphoblastic leukaemia / syndrome / overt acute lymphoblastic leukaemia / TEL-AML1-positive disease / chromosome-positive acute lymphoblastic leukaemia / paediatric acute lymphoblastic leukaemia using high-resolution single nucleotide polymorphism arrays / fairly non-pathological infections / / MedicalTreatment molecular therapeutics / cranial irradiation / combination chemotherapy / chemotherapy / radiation / treatment protocols / remission induction / / Organization Harvard Medical School / St Jude Children’s Research Hospital / IMC / University of Tennessee / Dana-Farber Cancer Institute / Department of Pediatric Oncology / Department of Epidemiology and Cancer Control / Department of Oncology / Tennessee Health Science Center / / Person Leslie L Robison / / Position important downstream mediator / / Product dexamethasone / cytarabine / cyclophosphamide / polyethylene glycol / thioguanine / mercaptopurine / prednisolone / valproic acid / prednisone / hydrocortisone / doses / / ProvinceOrState Aurora / Tennessee / / Technology ADAM / radiation / antibodies / transplantation / stem cells / DNA binding / pharmacokinetics / single nucleotide polymorphism / Pharmacogenetics / four consecutive treatment protocols / DNA synthesis / DNA Chip / chemotherapy / pharmacodynamics / genotype / / URL www.thelancet.com / / SocialTag 
Seminar Acute lymphoblastic leukaemia Ching-Hon Pui, Leslie L Robison, A Thomas Look Lancet 2008; 371: 1030–43 Department of Oncology